Who are PEG-rhGH Injection + Semaglutide Injection's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-rhgh-injection-semaglutide-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

PEG-rhGH Injection + Semaglutide Injection — Competitive Intelligence Brief

PEG-rhGH Injection + Semaglutide Injection (PEG-rhGH Injection + Semaglutide Injection) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Growth hormone analog + GLP-1 receptor agonist combination. Area: Endocrinology; Metabolic disorders.

marketed Growth hormone analog + GLP-1 receptor agonist combination Growth hormone receptor; GLP-1 receptor Endocrinology; Metabolic disorders Small molecule Live · refreshed every 30 min

Target snapshot

PEG-rhGH Injection + Semaglutide Injection (PEG-rhGH Injection + Semaglutide Injection) — Shanghai Zhongshan Hospital. This combination therapy stimulates growth hormone secretion via PEG-rhGH while simultaneously activating GLP-1 receptors through semaglutide to promote metabolic effects and weight management.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PEG-rhGH Injection + Semaglutide Injection TARGET	PEG-rhGH Injection + Semaglutide Injection	Shanghai Zhongshan Hospital	marketed	Growth hormone analog + GLP-1 receptor agonist combination	Growth hormone receptor; GLP-1 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Growth hormone analog + GLP-1 receptor agonist combination class)

Shanghai Zhongshan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PEG-rhGH Injection + Semaglutide Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-rhgh-injection-semaglutide-injection. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab